Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC<sub>50</sub>and [I<sub>2</sub>]/IC<sub>50</sub>, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies

DOI Web Site 被引用文献3件
  • Jack A. Cook
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Bo Feng
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Katherine S. Fenner
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Sarah Kempshall
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Ray Liu
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Charles Rotter
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Dennis A. Smith
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Matthew D. Troutman
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Mohammed Ullah
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California
  • Caroline A. Lee
    Departments of Clinical Pharmacology, Pharmacokinetics, Dynamics & Metabolism, and Preclinical Statistics, Pfizer Global Research & Development, Groton/New London, Connecticut, Sandwich, U.K., and La Jolla, California

この論文をさがす

収録刊行物

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ